
Precision, speed, impact: Evolving mass spectrometry for med...
MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Newsletters and Deep Dive digital magazine
MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Editor's Picks
Newsletters and Deep Dive
digital magazine